Format

Send to

Choose Destination
Lancet Oncol. 2016 Nov;17(11):e469. doi: 10.1016/S1470-2045(16)30520-4.

Vemurafenib for BRAFV600E-positive metastatic papillary thyroid cancer - Authors' response.

Author information

1
Department of Otorhinolaryngology, Head and Neck Surgery, University of Pennsylvania, Stellar-Chance Laboratories, Mezzanine, 422 Curie Boulevard, Philadelphia, PA 19104, USA; Abramson Cancer Center, Department of Medicine, Haematology/Oncology, University of Pennsylvania, Stellar-Chance Laboratories, Mezzanine, 422 Curie Boulevard, Philadelphia, PA 19104, USA. Electronic address: brosem@mail.med.upenn.edu.
2
Abramson Cancer Center, Department of Medicine, Haematology/Oncology, University of Pennsylvania, Stellar-Chance Laboratories, Mezzanine, 422 Curie Boulevard, Philadelphia, PA 19104, USA.
PMID:
27819236
DOI:
10.1016/S1470-2045(16)30520-4
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center